Evidence map›Paper›PMID 35337028›Full record

ArticleViruses2022

An Improved αvβ6-Receptor-Expressing Suspension Cell Line for Foot-and-Mouth Disease Vaccine Production.

Yongjie Harvey, Ben Jackson, Brigid Veronica Carr, Kay Childs, Katy Moffat, Graham Freimanis, Chandana Tennakoon, Nicholas Juleff, Julian Seago

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Yongjie HarveyThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.
Ben JacksonThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.
Brigid Veronica CarrThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.
Kay ChildsThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.
Katy MoffatThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.
Graham FreimanisThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.ORCID 0000-0001-8186-2638
Chandana TennakoonThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.
Nicholas JuleffBill & Melinda Gates Foundation, 500 5th Ave. N, Seattle, WA 98109, USA.ORCID 0000-0002-0402-9658
Julian SeagoThe Pirbright Institute, Ash Road, Woking GU24 0NF, UK.ORCID 0000-0002-9012-9830
The Pirbright Institute · GBGates Foundation · US

Funding

Biotechnology and Biological Sciences Research Council BBS/E/I/00007037Biotechnology and Biological Sciences Research Council BBS/E/I/00007039
6 · The paper itself

Abstract

Foot-and-mouth disease (FMD) is endemic in large parts of sub-Saharan Africa, Asia and South America, where outbreaks in cloven-hooved livestock threaten food security and have severe economic impacts. Vaccination in endemic regions remains the most effective control strategy. Current FMD vaccines are produced from chemically inactivated foot-and-mouth disease virus (FMDV) grown in suspension cultures of baby hamster kidney 21 cells (BHK-21). Strain diversity means vaccines produced from one subtype may not fully protect against circulating disparate subtypes, necessitating the development of new vaccine strains that "antigenically match". However, some viruses have proven difficult to adapt to cell culture, slowing the manufacturing process, reducing vaccine yield and limiting the availability of effective vaccines, as well as potentiating the selection of undesired antigenic changes. To circumvent the need to cell culture adapt FMDV, we have used a systematic approach to develop recombinant suspension BHK-21 that stably express the key FMDV receptor integrin αvβ6. We show that αvβ6 expression is retained at consistently high levels as a mixed cell population and as a clonal cell line. Following exposure to field strains of FMDV, these recombinant BHK-21 facilitated higher virus yields compared to both parental and control BHK-21, whilst demonstrating comparable growth kinetics. The presented data supports the application of these recombinant αvβ6-expressing BHK-21 in future FMD vaccine production.

Indexed as

Foot-and-Mouth DiseaseFoot-and-Mouth Disease VirusViral VaccinesAnimalsCell LineVaccinationViral VaccinesFMDVfoot-and-mouth diseasesuspension BHK-21vaccine

Identifiers

PMID35337028
PMCPMC8951101
OpenAlexW4220720335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.